Syros Pharmaceuticals, Inc. (SYRS)
$
0.03
Key metrics
Financial statements
Free cash flow per share
-2.5480
Market cap
805 Thousand
Price to sales ratio
2.0854
Debt to equity
-5.4145
Current ratio
2.2517
Income quality
1.0225
Average inventory
0
ROE
-27.4684
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Syros Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing treatments for cancer and monogenic diseases while establishing a pipeline of gene control medicines. The financial data pertains to the fiscal year 2023. The company recorded an operating income of -$128,988,000.00 reflecting its earnings from core operations. Its lead product candidates include Tamibarotene, a selective retinoic acid receptor alpha agonist currently undergoing a Phase III clinical trial for a genomically defined subset of patients with myelodysplastic syndrome, as well as a Phase II clinical trial for patients with acute myeloid leukemia. Additionally, the innovative SY-2101, an oral formulation of arsenic trioxide, aims to treat acute promyelocytic leukemia, and SY-5609, a cyclin-dependent kinase 7 inhibitor, is in a Phase I clinical trial for patients with select advanced solid tumors. The weighted average number of diluted shares outstanding is 28,325,779.00 reflecting potential dilution effects. The diluted EPS is -$5.81 accounting for potential share dilution, and the EBITDA is -$157,195,000.00 a key indicator of the company's operational profitability. The company maintains a collaboration and option agreement with Incyte Corporation focusing on therapeutic target discovery in myeloproliferative neoplasms, alongside a licensing agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. Originally known as LS22, Inc., the company rebranded to Syros Pharmaceuticals, Inc. in August 2012 and has been incorporated since 2011, headquartered in Cambridge, Massachusetts. In terms of stock performance, the stock is affordable at $0.03 making it suitable for budget-conscious investors. With a market capitalization of $838,515.00 the company is classified as a small-cap player. Furthermore, the stock has a high average trading volume of 24,774,864.00 indicating strong liquidity in the market. As a key player in the Biotechnology industry, Syros Pharmaceuticals significantly contributes to the overall market landscape. It operates within the Healthcare sector, driving innovation and growth through its focused therapeutic developments and strategic agreements.
What is Syros Pharmaceuticals, Inc. (SYRS)'s stock forecast?
Analysts predict Syros Pharmaceuticals, Inc. stock to fluctuate between $0.03 (low) and $6.93 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Syros Pharmaceuticals, Inc.'s market capitalization?
As of 2025-04-01, Syros Pharmaceuticals, Inc.'s market cap is $838,515, based on 27,950,500 outstanding shares.
How does Syros Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Syros Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Syros Pharmaceuticals, Inc. (SYRS) stock?
To buy Syros Pharmaceuticals, Inc. (SYRS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SYRS. Place an order (Market, Limit, etc.).
What is the best time to invest in Syros Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Syros Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $9,936,000 | EPS: -$5.81 | Growth: 48.97%.
Where can I find Syros Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.syros.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Syros Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Syros Pharmaceuticals, Inc. stock?
All-time high: $134.60 (2021-02-10) | All-time low: $0.02 (2025-03-27).
What are the key trends affecting Syros Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
benzinga.com
Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression did not meet its primary endpoint of complete response (CR) rate. Tamibarotene is Syr.
accesswire.com
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
seekingalpha.com
Syros Pharmaceuticals, Inc (NASDAQ:SYRS ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Karen Hunady - Director of Investor Relations and Corporate Communications Conley Chee - Chief Executive Officer David Roth - Chief Medical Officer Jason Haas - Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Phil Nadeau - TD Cowen Jason Butler - JMP Citizens Leah Cann - Brookline Capital Markets Operator Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2024 and provided a business update. “It is a very exciting time at Syros, as we approach a significant milestone in our efforts to establish tamibarotene as a potential new standard of care for higher-risk myelodysplastic synd.
accesswire.com
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
See all news
